Avalo Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avalo Therapeutics (Nasdaq: AVTX) said its management will present at two investor conferences in February 2026: a Guggenheim Emerging Outlook Biotech Summit fireside chat on February 11, 2026 at 10:00 AM ET and an Oppenheimer Healthcare Life Sciences fireside chat on February 25, 2026 at 10:00 AM ET.

Live webcasts and replays will be posted under News / Events on the Avalo Therapeutics investor website, with archived webcasts available for at least 30 days.

News Market Reaction

-9.96%

7 alerts

-9.96% News Effect

-10.2% Trough in 11 hr 50 min

-$32M Valuation Impact

$289M Market Cap

1.2x Rel. Volume

On the day this news was published, AVTX declined 9.96%, reflecting a notable negative market reaction. Argus tracked a trough of -10.2% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $32M from the company's valuation, bringing the market cap to $289M at that time.

Data tracked by StockTitan Argus on the day of publication.

WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Guggenheim Emerging Outlook: Biotech Summit 2026
Fireside Chat
February 11, 2026, at 10:00 am ET

Oppenheimer 36th Annual Healthcare Life Sciences Conference
Fireside Chat
February 25, 2026, at 10:00 am ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.

About AVTX-009 

AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.¹ It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune-mediated inflammatory diseases.^1-3

References:¹Dinarello CA. Immunol Rev. 2018;281(1):8-27. ²Kany S et al. Int J Mol Sci. 2019;20(23):6008. ³Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.

For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

FAQ

When will Avalo Therapeutics (AVTX) present at the Guggenheim Emerging Outlook Biotech Summit?

Avalo Therapeutics will present on February 11, 2026 at 10:00 AM ET. According to Avalo Therapeutics, management will appear as part of a fireside chat and a live webcast will be available on the investor website.

How can investors watch Avalo Therapeutics (AVTX) at the Oppenheimer Healthcare Life Sciences Conference on February 25, 2026?

Investors can watch the February 25, 2026 fireside chat via a live webcast when available. According to Avalo Therapeutics, the webcast and replay will be posted under News / Events on the company investor website.

Will Avalo Therapeutics (AVTX) make replays of the February 2026 conference webcasts available?

Yes, archived webcasts will be available for replay for at least 30 days. According to Avalo Therapeutics, replays and any live webcast links will appear in the Investors section under News / Events on the company website.

Where on the Avalo Therapeutics (AVTX) website will conference webcasts be posted?

Webcasts and replays will be posted under News / Events in the Investors section. According to Avalo Therapeutics, the investor site at https://ir.avalotx.com will host live webcasts and archived replays.

What topics will Avalo Therapeutics (AVTX) management likely discuss during the February 2026 fireside chats?

Management is expected to discuss the company’s clinical-stage IL-1β programs and corporate updates during the fireside chats. According to Avalo Therapeutics, presentations will cover recent clinical and strategic developments relevant to investors.